Skip to main content
. 2021 May 28;100(21):e26075. doi: 10.1097/MD.0000000000026075

Table 1.

Baseline characteristics.

Demographics Failure group (n = 28) Success group (n = 15) P
Age, yr 39.0 (32.0–45.0) 37.0 (33.0–42.0) .006
BMI, kg/m2 22.0 (18.0–29.0) 21.8 (15.0–29.0) .908
Gravida 0 (0–8) 1 (0–3) .685
Parity 0 (0–1) 0 (0) .295
Symptom
 Pain score (NRS) 8 (7–10, n = 20) 8.0 (1–10, n = 13) .609
 Menorrhagia (n) 24 (85.7%) 10 (66.7%) .238
AMH, ng/mL 0.54 (0.01–8.54) 2.91 (0.34–7.92) .002
CA125, IU/mL 151.5 (13.0–809.1) 182.0 (29.2–1388) .752
Infertility duration (yr) 5.0 (0–16) 3.0 (0–11) .119
Preoperative uterine volume, cm3 353.67 (93.0–2097.7) 327.76 (134.4–743.6) .262
Nodule weight, g 123.5 (3.0–320.0) 90.0 (3.0–240.0) .333
Operative time, min 220.0 (68.0–440.0) 175.0 (65.0–305.0) .048
EBL, mL 750 (100–2500) 500 (50–2000) .016
Surgical platform .977
 Robot (n) 5 (17.9%) 2 (13.3%)
 Laparoscopy (n) 7 (25.0%) 5 (33.3%)
 Laparotomy (n) 16 (57.1%) 8 (53.3%)
Endometrium distortion (n) 10 (35.7%) 8 (53.3%) .264
Adenomyosis type .073
 Focal (n) 4 (14.3%) 6 (40.0%)
 Diffuse (n) 24 (85.7%) 9 (60.0%)
Transfusion (n) 19 (67.9%) 6 (40.0%) .078
Combined disease
 Endometriosis (n) 8 (28.6%) 8 (53.3%) .109
 Combined leiomyoma (n) 12 (42.9%) 6 (40.0%) .856
Size of myoma, cm 2.5 (1.0–5.9) 2.2 (1.0–4.9) .553
Number of myoma 2 (1–4) 2 (1–3) .892
Endometriosis size, cm 4.6 (1.0–10.0) 3.5 (1.0–8.5) .755
ASRM stage 4 (1–4) 4 (3–4) .755
IVF history (n) 25 (89.3%) 12 (80.0%) 1.00
The number of pregnancy trial after surgery 2 (0–5) 1 (0–4) .848
Follow-up duration, mo 18.5 (3–42) 12.0 (6–38) .256